ABSTRACT
Calciphylaxis, also known as Calcific uremic arteriolopathy (CUA), is a serious disorder that presents with skin necrosis due to calcification of dermal and subcutaneous adipose tissue capillaries and arterioles. The condition occurs primarily in patients with end-stage renal disease (ESRD) on dialysis, and it carries high morbidity and mortality, primarily due to sepsis, with an estimated six-month survival of approximately 50%. Although there are no high-quality studies to guide the optimal treatment approach for patients with calciphylaxis, many retrospective studies and case series support treatment with sodium thiosulfate (STS). Despite the frequent use of STS as an off-label treatment, data regarding its safety and efficacy are limited. STS has generally been considered a safe drug with mild side effects. However, severe metabolic acidosis associated with STS is a rare and life-threatening complication of STS treatment and is often unpredictable. Herein, we report a 64-year-old female with ESRD on peritoneal dialysis (PD) who presented with a profound high anion gap metabolic acidosis and severe hyperkalemia while on STS treatment for CUA. No other etiology for her severe metabolic acidosis other than STS was identified. ESRD patients receiving STS should be monitored closely for this side effect. Dose reduction, increasing the duration of infusion, or even discontinuing STS treatment should be considered if severe metabolic acidosis develops.
Subject(s)
Acidosis , Calciphylaxis , Kidney Failure, Chronic , Thiosulfates , Female , Humans , Middle Aged , Calciphylaxis/diagnosis , Calciphylaxis/drug therapy , Calciphylaxis/etiology , Renal Dialysis/adverse effects , Retrospective Studies , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/therapy , Acidosis/etiologyABSTRACT
⺠Prednisone therapy to treat nephrotic syndrome ⺠Diffuse maculopapular rash ⺠Pruritis.
